Chico’s FAS, Inc. (CHS) rose 24.01% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -33.85% and is now down by -32.65% since start of this year. A look at its monthly performance shows that the stock has recorded a -23.75% fall over the past 30 days. Its equity price dipped by -31.41% over the past three months which led to its overall six-month decrease to stand at -33.03%.

Experts from research firms are bullish about the near-term performance of Chico’s FAS, Inc. with most of them predicting a $5.5 price target on a short-term (12 months) basis. The average price target by the analysts will see a -7.41% rise in the stock and would lead to CHS’s market cap to surge to $678.54M. The stock has been rated an average 3, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 9 analysts that track Chico’s FAS, Inc. (NYSE:CHS) and find out that 7 of them rated it as a Hold. 1 of the 2 analysts rated it as a Buy or a Strong Buy while 1 advised investors to desist from buying the stock or sell it if they already possess it.

A look at CHS technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 38.63 point. Its trading volume has added 2390578 shares compared to readings over the past three months as it recently exchanged 5770578 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 3380000 shares, and this is 1.71 times the normal volume.

Analysts have predicted a price target for Invacare Corporation (IVC) for 1 year and it stands at an average $13.67/share. This means that it would likely increase by 192.72% from its current position. The current price of the stock has been moving between $4.66 and $5.1. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $7. On the other hand, one analyst is super bullish about the price, setting a target as high as $17.

Analysts view Invacare Corporation (NYSE:IVC) as a Hold, with 2.3 consensus rating. Reuters surveyed 4 analysts that follow IVC and found that 2 of those analysts rated the stock as a Hold. The remaining 2 were divided, with 2 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Invacare Corporation (IVC) shares or sell it if they already own it.